vs
铱星通信（IRDM）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Bio-Techne的季度营收约是铱星通信的1.4倍（$311.4M vs $219.1M），Bio-Techne净利率更高（16.4% vs 9.9%，领先6.5%），铱星通信同比增速更快（1.9% vs -1.5%），过去两年铱星通信的营收复合增速更高（4.4% vs 1.3%）
铱星通信是一家总部位于美国弗吉尼亚州麦克莱恩的上市企业，运营着由80颗卫星组成的铱星星座，其中66颗为工作星，14颗为在轨备用星。其卫星网络支持手持卫星电话、卫星通信终端及集成收发设备实现全球范围的语音和数据传输，还可提供双向卫星消息服务，满足全球各场景的通信需求。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
IRDM vs TECH — 直观对比
营收规模更大
TECH
是对方的1.4倍
$219.1M
营收增速更快
IRDM
高出3.5%
-1.5%
净利率更高
TECH
高出6.5%
9.9%
两年增速更快
IRDM
近两年复合增速
1.3%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.1M | $311.4M |
| 净利润 | $21.6M | $51.0M |
| 毛利率 | — | 66.9% |
| 营业利润率 | 23.2% | 24.2% |
| 净利率 | 9.9% | 16.4% |
| 营收同比 | 1.9% | -1.5% |
| 净利润同比 | — | 126.0% |
| 每股收益（稀释后） | — | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IRDMTECH
| Q1 26 | $219.1M | $311.4M | ||
| Q4 25 | $212.9M | $295.9M | ||
| Q3 25 | $226.9M | — | ||
| Q2 25 | $216.9M | $317.0M | ||
| Q1 25 | $214.9M | $316.2M | ||
| Q4 24 | $213.0M | $297.0M | ||
| Q3 24 | $212.8M | $289.5M | ||
| Q2 24 | $201.1M | $306.1M |
净利润IRDMTECH
| Q1 26 | $21.6M | $51.0M | ||
| Q4 25 | $24.9M | $38.0M | ||
| Q3 25 | $37.1M | — | ||
| Q2 25 | $22.0M | $-17.7M | ||
| Q1 25 | $30.4M | $22.6M | ||
| Q4 24 | $36.3M | $34.9M | ||
| Q3 24 | $24.4M | $33.6M | ||
| Q2 24 | $32.3M | $40.6M |
毛利率IRDMTECH
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
营业利润率IRDMTECH
| Q1 26 | 23.2% | 24.2% | ||
| Q4 25 | 25.9% | 18.4% | ||
| Q3 25 | 30.9% | — | ||
| Q2 25 | 23.2% | -7.5% | ||
| Q1 25 | 28.1% | 12.2% | ||
| Q4 24 | 24.5% | 16.0% | ||
| Q3 24 | 25.8% | 13.8% | ||
| Q2 24 | 21.7% | 15.0% |
净利率IRDMTECH
| Q1 26 | 9.9% | 16.4% | ||
| Q4 25 | 11.7% | 12.8% | ||
| Q3 25 | 16.4% | — | ||
| Q2 25 | 10.1% | -5.6% | ||
| Q1 25 | 14.2% | 7.1% | ||
| Q4 24 | 17.1% | 11.7% | ||
| Q3 24 | 11.5% | 11.6% | ||
| Q2 24 | 16.1% | 13.3% |
每股收益（稀释后）IRDMTECH
| Q1 26 | — | $0.32 | ||
| Q4 25 | $0.24 | $0.24 | ||
| Q3 25 | $0.35 | — | ||
| Q2 25 | $0.20 | $-0.11 | ||
| Q1 25 | $0.27 | $0.14 | ||
| Q4 24 | $0.30 | $0.22 | ||
| Q3 24 | $0.21 | $0.21 | ||
| Q2 24 | $0.27 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $209.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $2.1B |
| 总资产 | — | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IRDMTECH
| Q1 26 | — | $209.8M | ||
| Q4 25 | $96.5M | $172.9M | ||
| Q3 25 | $88.5M | — | ||
| Q2 25 | $79.3M | $162.2M | ||
| Q1 25 | $50.9M | $140.7M | ||
| Q4 24 | $93.5M | $177.5M | ||
| Q3 24 | $159.6M | $187.5M | ||
| Q2 24 | $63.5M | $152.9M |
总债务IRDMTECH
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $1.8B | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
股东权益IRDMTECH
| Q1 26 | — | $2.1B | ||
| Q4 25 | $462.6M | $2.0B | ||
| Q3 25 | $450.5M | — | ||
| Q2 25 | $473.6M | $1.9B | ||
| Q1 25 | $518.4M | $2.0B | ||
| Q4 24 | $576.6M | $2.1B | ||
| Q3 24 | $663.8M | $2.1B | ||
| Q2 24 | $786.7M | $2.1B |
总资产IRDMTECH
| Q1 26 | — | $2.6B | ||
| Q4 25 | $2.5B | $2.5B | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | $2.6B | ||
| Q1 25 | $2.6B | $2.6B | ||
| Q4 24 | $2.7B | $2.7B | ||
| Q3 24 | $2.8B | $2.7B | ||
| Q2 24 | $2.7B | $2.7B |
负债/权益比IRDMTECH
| Q1 26 | — | — | ||
| Q4 25 | 3.80× | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 3.05× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IRDM
| Voice and data | $57.4M | 26% |
| IoT data (2) | $46.0M | 21% |
| Government | $39.5M | 18% |
| Government service revenue (5) | $27.6M | 13% |
| Subscriber equipment | $20.2M | 9% |
| Hosted payload and other data service (4) | $14.8M | 7% |
| Broadband (3) | $12.2M | 6% |
| Commercial | $1.3M | 1% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
